Eyevensys, a Paris-based biotechnology company, has closed a round of $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis, according to a press release.
The funds will be used to launch the phase 2 Electro study of EYS606 in the United States, as well as to further advance preclinical development of other proteins targeted for use in retinal and other ophthalmic diseases.
EYS606, which uses the company’s proprietary electrotransfection system to sustain therapeutic proteins delivered into the ciliary muscle, is in phase
Uncategorized